Boston Scientific Partners with ParkwayHealth and Yiran Urology to Advance BPH Treatment in China

ShanghaiAugust 10, 2022PR Newswire -- Boston Scientific (NYSE:BSX), a global leader in medical technology, has partnered with ParkwayHealth and YlRAN UROLOGY to establish the "Urology Joint Innovation Center" and the "Rezūm Academic Exchange and Training Center." Rezūm, part of Boston Scientific's portfolio, (Rezūm) The first commercial device of the ReDream system, including thermal vapor therapy equipment and disposable prostate thermal vapor therapy instruments, has officially completed installation at the center on mainland China. Starting from this point, the three parties will integrate their resource advantages in products, technology, and platforms to jointly promote the innovation and upgrading of treatment technologies in China's urology field, allowing cutting-edge global medical achievements to benefit Chinese patients as soon as possible.

"Urology Joint Innovation Center", "ReDream Academic Exchange and Training Center" Unveiling Ceremony

The First Commercial ReDream Device in Mainland China Installed at Shanghai Xinarui Medical Center under ParkwayHealth

For Common Diseases in Middle-Aged and Elderly, Accelerate the Introduction of Groundbreaking Treatment Technologies

Benign Prostatic Hyperplasia (BPH) is a highly prevalent condition causing urinary obstruction in middle-aged and elderly men. More than half of men over 50 worldwide suffer from BPH, and the prevalence rate reaches up to 90% in men over 80.^[1]. With the acceleration of the aging population process, the disease burden of BPH will also increase day by day.

Against this backdrop, the Boston Scientific Rezūm System has pioneered an ultra-minimally invasive thermal vapor therapy that can be performed under local anesthesia. It utilizes the release of thermal energy from high-temperature water vapor to instantly necrotize prostate tissue cells, which are then naturally absorbed by the body, thereby achieving the goal of reducing prostate volume and improving clinical symptoms. The average procedure time is only 5-8 minutes, and patients' sexual function can be well preserved post-operation.

In December 2020, this innovative product benefited Chinese patients in advance through the "pilot first" program in Boao Lecheng International Medical Tourism Pilot Zone in Hainan, and launched a real-world study project. Less than 15 months later, in March this year, it successfully obtained registration approval from the National Medical Products Administration.

"Boston Scientific China Vice President of Peripheral and Oncology Interventions, Urology and Pelvic Health, and Device Services, Da Bo, stated: 'From the first "Pilot First" surgery to the activation of the first commercial ReDream device today, the approval and commercialization process of ReDream has demonstrated "China Speed." We look forward to the new journey where ReDream can help more Chinese patients benefit faster, enabling a large number of middle-aged and elderly men to overcome the distress of unspoken problems.'"

Join Hands with Local Medical Partners to Advance the Treatment of Urological Diseases

To accelerate the accessibility of the Rezūm system in clinical settings in China and benefit Chinese BPH patients more quickly, Boston Scientific has actively developed diversified access channels. It has taken the lead in collaborating with ParkwayHealth and YlRAN UROLOGY team in areas such as clinical diagnosis and treatment services, and surgical training exchanges, leading the advancement and upgrade of treatment technologies in the field of BPH in China.

Li Zhiping, Executive President of Greater China for ParkwayHealth, stated: "ParkwayHealth, which belongs to IHH Healthcare, the world's second-largest healthcare group by market value, focuses on patient-centered medical services. Boston Scientific is an international leading medical device company that constantly innovates and serves patients. We share the same philosophy of caring for life. I sincerely hope that through our cooperation, we can achieve mutual benefits and development. I also believe that with the professional empowerment of the YlRAN UROLOGY expert team, we can popularize new technologies and bring benefits to more patients."

Professor Huang Yiran, Chief Expert of YlRAN UROLOGY, stated: "YlRAN UROLOGY has been collaborating with ParkwayHealth for two years, and today I am very pleased to witness the first commercial unit of Boston Scientific's Rezūm System being installed at ParkwayHealth. This new technology is minimally invasive with few side effects, which is particularly important for elderly patients. I wish this collaboration every success and look forward to us working together to contribute to the health of the people in Shanghai and across China."

Vice President of Health Economics, Government Affairs and Public Relations at Boston Scientific China, Ping Xu, stated: "This collaboration between Boston Scientific, Parkway Healthcare, and YlRAN UROLOGY marks a successful attempt in exploring innovative access channels outside of public hospitals. Moving forward, Boston Scientific looks forward to co-creating, co-building, and achieving mutual success with more outstanding local partners, accelerating the commercial implementation of globally innovative clinical outcomes, and making high-quality medical services meeting international standards accessible to Chinese patients as soon as possible."

*Registration Certificate No.: Thermal vapor therapy device, China Medical Device Registration Import 20223090122; Single-use prostate thermal vapor therapy device, China Medical Device Registration Import 20223090123

About Boston Scientific

Boston Scientific Corporation is committed to innovating for life. We are dedicated to pioneering medical solutions that improve the lives of patients around the world. For over four decades, Boston Scientific has been at the forefront of the global medical technology industry, delivering a wide range of high-performance medical solutions to meet critical patient needs, while reducing healthcare costs. For more detailed information, please visit the company's website:www.bostonscientific.cn

About Boston Scientific Greater China

Boston Scientific established its China headquarters in Shanghai in 1997 and currently has branch offices in Beijing, Shanghai, Guangzhou, Chengdu, Hong Kong, and Taiwan. The company's core businesses cover cardiac intervention, structural heart disease, cardiac rhythm management and electrophysiology, endoscopic intervention, peripheral and tumor intervention, urology and pelvic floor health, respiratory products, and more. Upholding its tradition as an innovation leader, Boston Scientific is committed to becoming a respected medical technology company that meets the needs of doctors and patients, demonstrates innovative vitality, and provides high-quality medical products and services for prevention, diagnosis, and treatment. For more detailed information, please visit the company’s website:www.bostonscientific.cn

^[1] Bin LK. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. Elsevier Ltd. 2017;4(3):148–51.